In the wake of the Food and Drug Administration’s (FDA’s) controversial decision to approve aducanumab for Alzheimer’s disease, how will, and how should, Medicare respond? We propose a coverage with ...
The Centers for Medicare & Medicaid Services (CMS) issued a ground-breaking draft national coverage decision (NCD) on January 11, 2022, for Food & Drug Administration (FDA) approved monoclonal ...
Recent changes to Medicare's prescription drug benefit were designed to make coverage more generous for beneficiaries while shifting more financial risk onto insurers. The Inflation Reduction Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback